The STARS (steroids against re-stenosis) trial: the use of peri-procedural oral corticosteriods to prevent in-segment re-stenosis after percutaneous coronary intervention
| ISRCTN | ISRCTN05886349 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN05886349 |
| Secondary identifying numbers | CTA number: 22011/0001/001-0001 |
- Submission date
- 03/10/2006
- Registration date
- 02/08/2007
- Last edited
- 19/05/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Andrew Turley
Scientific
Scientific
The James Cook University Hospital
Department of Cardiology
Cardiothoracic Research Department
Red Portacabin
Marton Road
Middlesbrough
TS4 3BW
United Kingdom
| a.turley@btopenworld.com |
Study information
| Study design | Double blind 2 x 2 randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | The STARS (STeroids Against Re-Stenosis) trial: the use of peri-procedural oral corticosteriods to prevent in-segment re-stenosis after percutaneous coronary intervention |
| Study acronym | The STARS (STeroids Against Re-Stenosis) trial |
| Study objectives | 1. The peri-procedural use of oral corticosteroids in elective/acute patients undergoing percutaneous coronary intervention reduces the incidence of in-segment re-stenosis 2. The use of a chromium cobalt stent results in lower restenosis rates than bare metal stents in elective/acute patients undergoing percutaneous coronary intervention |
| Ethics approval(s) | London Multicentre Research Ethics Committee (MREC), 05/05/2005, ref: 04/MREC2/061 |
| Health condition(s) or problem(s) studied | Atherosclerosis |
| Intervention | 1. Prednisolone versus placebo 2. Chromium cobalt stent versus stainless steel stents Steroid randomisation procedure: Acute cases: patients will be randomised via block randomisation 24 hours before their procedure and assigned to the respective study arms by a closed envelope system Elective cases: patients will be randomised via block randomisation at the time of their pre-admission clinic attendance (one-week prior to the procedure) and assigned to the respective study arms by a closed envelope system Stent randomisation procedure: Acute and elective cases: patients will be randomised via block randomisation at the time of their percutaneous coronary intervention procedure if no exclusion criteria are met and assigned to the respective study arms by a closed envelope system. Steroid protocol: Patients will be randomised to oral prednisolone or placebo. Patients will receive prednisolone 40 mg to start 24 hours pre-procedure and to continue for a total of 28-days. Due to dual oral antiplatelet therapy plus oral corticosteroid use, all patients will receive empirical proton pump inhibitor cover (lansoprazole 15 mg/day for 28 days) for the duration of the corticosteroid course (advice taken from a consultant gastroenterologist). Protocol for steroid withdrawal/step-down: Due to the potential risk of adrenal suppression all patients will receive a step-down approach for steroid withdrawal. For the first 14 days patients will receive 40 mg prednisolone. The dose will then be tailed off over the next 14 days as shown below: Day 1 to 14 = 40 mg Day 15 to 19 = 20 mg Day 20 to 24 = 10 mg Day 25 to 28 = 5 mg Registry: Patients' full eligibility for study participation will not be known until the time of coronary angiography as a major inclusion criteria is a lesion of a reference diameter vessel greater than or equal to 3 mm. Lesions less than 3 mm are an exclusion criteria as National Institute for Clinical Excellence (NICE) guidelines advise the use of drug eluting stents in this setting. Therefore some patients will receive study medication up to this point. A registry will be kept of these patients and they will be followed up clinically (via telephone) but not angiographically. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Corticosteroids |
| Primary outcome measure | Angiographically documented in-segment re-stenosis. |
| Secondary outcome measures | 1. Late loss 2. Target lesion revascularisation: defined as repeat intervention of re-stenotic lesions, which include the target site of the stent implantation or 5 mm proximal and distal in the same epicardial coronary artery 3. Target vessel revascularisation: defined as repeat intervention within the same epicardial coronary artery 4. Target vessel failure: target vessel revascularisation plus any peri-procedural complication related to the procedure 5. Myocardial Infarction (MI) related to the target vessel 6. Incidence of death 7. Unstable angina, congestive cardiac failure 8. Non-fatal MI 9. Q wave MI 9. Non-Q wave MI 10. Cardio-Vascular Accident (CVA) 11. Intracranial haemorrhage 12. Infarction 13. Repeat hospitalisation 14. Major/minor bleeding complications 15. Poor glycaemic control |
| Overall study start date | 01/01/2006 |
| Completion date | 01/01/2009 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | 548 |
| Key inclusion criteria | 1. Any patient awaiting percutaneous coronary intervention for symptomatic coronary artery disease (elective or acute) 2. Documented myocardial ischaemia 3. Coronary angiography demonstrating at least a 50% reduction of the luminal diameter in at least one native coronary artery (as measured by quantitative computerised angiography) 4. Any lesion more than 3 mm diameter |
| Key exclusion criteria | 1. Proposed use of a drug eluting stent (in the study vessel[s]) 2. Left Main Stem stenosis 3. Primary Percutaneous Coronary Intervention (PCI) for ST elevation myocardial infarction 4. Steroid therapy within 30-days of study enrolment 5. Contraindication to corticosteroid use 6. Previous inclusion in this study 7. Non-cardiac disease likely to cause death within six months 8. Inter-hospital transfers from Cumbria |
| Date of first enrolment | 01/01/2006 |
| Date of final enrolment | 01/01/2009 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
The James Cook University Hospital
Middlesbrough
TS4 3BW
United Kingdom
TS4 3BW
United Kingdom
Sponsor information
South Tees Hospitals NHS Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
c/o Dr David R Chadwick
Head of Research and Development
Marton Road
Middlesbrough
TS4 3BW
England
United Kingdom
| DavidRChadwick@stees.nhs.uk | |
| Website | http://www.southtees.nhs.uk/ |
"ROR" |
https://ror.org/02js17r36 |
Funders
Funder type
Government
South Tees Hospitals NHS Trust (UK) - Cardiothoracic Directorate Research and Development Department
No information available
Guidant Corporation (UK)
No information available
Cordis Corporation (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/08/2016 | Yes | No |
Editorial Notes
19/05/2016: Internal review
05/05/2016: Publication reference added.
